


# ONCOLOGY PORTFOLIO - Approved Products & Pipeline

INN /COMPOUND	CLASS	TARGET & MODALITY	INDICATION OR DISEASE
Vinorelbine	Chemotherapy	Vinca Alkaloid	Advanced <b>BREAST CANCER</b> as monotherapy or in combination with other agents
		Vinca Alkaloid	Advanced <b>NSCLC</b> as monotherapy or in combination with other chemotherapies
		Vinca Alkaloid	Adjuvant treatment of <b>NSCLC</b> in combination with platinum-based chemotherapy
Vinflunine	Chemotherapy	Vinca Alkaloid	Advanced or metastatic transitional-cell carcinoma of the <b>UROTHELIAL</b> tract
Neratinib <sup>1</sup>	Targeted therapy	Pan-HER inhibitor	HER2 amplified / overexpressed / HR+ early <b>BREAST CANCER</b> (extended adjuvant post trastuzumab based therapy)
Tabelecleucel <sup>2</sup>	Cell therapy	Allogeneic T-cell immunotherapy	Epstein-Barr virus associated post-transplant lymphoproliferative disease ( <b>EBV + PTLD</b> )
Encorafenib <sup>3</sup> / Binimetinib <sup>4</sup> (± other agents)	Targeted therapy	BRAF inhibitor + MEK inhibitor	Unresectable or metastatic <i>BRAF</i> <sup>V600</sup> -mutant <b>MELANOMA</b>
		BRAF inhibitor	Metastatic <i>BRAF</i> <sup>V600E</sup> -mutant <b>CRC</b> after prior systemic therapy
		BRAF inhibitor + MEK inhibitor	Metastatic <i>BRAF</i> <sup>V600E</sup> -mutant <b>NSCLC</b> <sup>5</sup>
		BRAF inhibitor + MEK inhibitor	Metastatic <i>BRAF</i> <sup>V600E</sup> -mutant <b>NSCLC</b> in Chinese population – OCEAN study
Exarafenib <sup>6</sup>	Targeted therapy	Pan-RAF small molecule inhibitor	<i>NRAS</i> mutant <b>MELANOMA</b> and other <i>BRAF</i> / <i>NRAS</i> mutant solid tumors
PFL-721 <sup>7</sup>	Targeted therapy	Mutant-selective EGFR-exon20 small molecule inhibitor	<b>NSCLC</b> with <i>EGFR</i> exon 20 insertion mutation
PFL-241 <sup>7</sup>	Targeted therapy	Mutant-selective 4 <sup>th</sup> generation EGFR small molecule inhibitor	<b>NSCLC</b> with <i>EGFR</i> exon 19/21 + C797S mutations
PFL-002 <sup>8</sup>	Targeted therapy	Anti-cMET antibody degrader	<b>NSCLC</b> / solid tumors with mutations or amplification of <i>MET</i>
Not-disclosed <sup>9</sup>	Targeted therapy	Multiple targets	<b>ONCOLOGY</b>



\*Approved at least by EMA. Vinorelbine was approved by National Health Authorities (before EU centralized procedure implementation).  
1.Commercialized in partnership with Puma Biotechnology. 2.Commercialized in partnership with Atara Biotherapeutics. 3.Encorafenib + cetuximab is approved for *BRAF*<sup>V600E</sup>-mutant mCRC, after prior systemic therapy. Encorafenib + binimetinib is approved for unresectable or metastatic *BRAF*-mutant melanoma, in adult patients. 4.Developed and launched in partnership with Array Biopharma (partnered with Pfizer since 2020). 5.Clinical development under Pfizer sponsorship. 6.Originated by Kinnate Biopharma Inc. Investigational Pan-RAF Inhibitor, Exarafenib, acquired by Pierre Fabre Laboratories. 7.Originated by Scorpion Therapeutics acquired by Pierre Fabre Laboratories. 8.Originated by Vertical Bio AG, acquired by Pierre Fabre Laboratories. 9.Discovery partnership with Vernalis Lt and RedRidge Bio.

This display includes ongoing clinical trials for both approved and investigational compounds. Inclusion in this display does not imply regulatory approval for these compounds or all indications.  
Products should be used in accordance with their prescribing information. Information about the trials can be found at [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov)